ArticleACR open rheumatology2025
Muscle Vasculitis: A Novel Delineation of Distinct Subsets of Disease.
Article in ACR open rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Asymmetrical muscular disorder with normal creatine kinase (CK) and electromyography (EMG): the challenging diagnosis of muscular polyarteritis nodosa (MPAN), case report and literature review.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Review
- Reply.ACR open rheumatology · 2026Article
- Severe muscle pain in the absence of enzyme elevation: a clue to the diagnosis of muscular vasculitis.ACR open rheumatology · 2026Article
- Vasculitic fasciitis characterizes a distinct subset of vasculitic myopathy with interferon-gamma signature.Acta neuropathologica · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe objective of this study was to assess the clinical and histopathologic features of muscle vasculitis.
methodsThe electronic database of SA Pathology, wherein all muscle biopsy samples in South Australia are assessed, was searched (2000-2023), identifying cases of vasculitis. Cases were classified as systemic vasculitis (SV) or isolated muscle vasculitis (IMV). IMV occurred as either localized muscle disease (IMV-LMD) or with known connective tissue disease (IMV-CTD). Clinical and histologic comparisons between muscle vasculitis and biopsy-proven idiopathic inflammatory myopathy (IIM) were made.
resultsFrom 3,090 muscle biopsy samples, 59 showed vasculitis (47.5% female, median age 64.1 [interquartile range (IQR) 51.5-75.3] years). SV was present in 32 of 59, IMV-LMD was present in 15 of 59, and IMV-CTD was present in 10 of 59. Patients with SV and IMV-LMD frequently had normal creatine kinase (CK) levels (SV: median 58.5 [IQR 25-152] IU/L; IMV-LMD: median 34.5 [IQR 21.5-88.5] IU/L). Antineutrophil cytoplasmic antibodies (ANCAs) were restricted to those with SV (myeloperoxidase-ANCA [13 of 32] vs proteinase 3-ANCA [2 of 32]). Compared to patients with IIM, patients with muscle vasculitis had less frequent weakness (29 of 59 vs 305 of 369; P < 0.01) but more distal muscle symptoms (21 of 59 vs 74 of 360; P = 0.02) and elevated C-reactive protein levels (35 of 59 vs 20 of 82; P < 0.01). Salient histologic features of IIM (lymphocytic infiltration of myofibers, myofiber necrosis, major histocompatibility complex class I up-regulation) occurred less frequently in muscle vasculitis than IIM (P < 0.01), suggesting myofiber integrity despite pathology in the vasculature.
conclusionMuscle vasculitis can occur with SV or be isolated to the muscles and is rarely associated with CTD. Distinct from IIM, muscle vasculitis frequently lacks myofiber necrosis and/or infiltration; consequent preservation of muscle power and normal CK levels should not deter from muscle biopsy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.